RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Clinical trials for RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New chemo cocktail aims to wipe out stomach cancer cells before surgery

Disease control Ongoing

This study is testing if adding a third chemotherapy drug (irinotecan) to the standard two-drug combination improves outcomes for people with operable stomach or gastroesophageal junction cancer. Patients receive four cycles of the three-drug chemo before surgery and four more cy…

Matched conditions: RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Phase: PHASE2 • Sponsor: Lund University Hospital • Aim: Disease control

Last updated Mar 30, 2026 14:35 UTC

RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Get alerted when new RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear

New chemo cocktail aims to wipe out stomach cancer cells before surgery